September 29, 2005 -- The IPO window opened again, with Avalon Pharma using a Google-like Dutch auction to fetch a price of $10.50 per share, Genomic Health priced 5 million shares at $12, the bottom of its range, Electro-Optical cut the asking price on its pending IPO in half, Forest Labs reported that milnacipran failed to help patients suffering from fibromyalgia, Schering won approval of Angeliq to treat moderate to severe symptoms of menopause, Lilly will add suicide risk to the warning label of its ADHD drug, plus Lilly said its sepsis drug was not effective for less severe forms of the disease, and Critical Therapeutics gained on news that the FDA re-approved an asthma treatment the company bought from Abbott Labs. The Centient Biotech 200™ closed almost 10 points higher at 3742, a rise of .26%. More details...
